UK cancer mutation testing firm Biofidelity raises $12m
pharmaphorum
AUGUST 21, 2020
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. This type of testing is usually carried out on lung tissue biopsies, which is an invasive and expensive procedure with a 10% failure rate.
57 
Let's personalize your content